Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgrastim + Chemotherapy vs Filgrastim Alone for Stem Cell Mobilization in Breast Cancer
NCT00002836Phase 3Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 1995
- Primary completion
- Mar 2006
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Cisplatin micelle injection (HA132), cyclophosphamide and etoposide in breast cancer (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Effectiveness of Chemotherapy + Filgrastim to Filgrastim Alone at 90 days. Started Sep 1995; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)cyclophosphamideetoposide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00002836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002836.